Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Fennec Pharmaceuticals, retaining the price target of $13.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors tied to Fennec’s growth trajectory and the outlook for PEDMARK. Even though 2025 revenue and earnings came in below his projections, he highlights that sales still grew 50% year over year and forecasts a sharp ramp in revenue and earnings through 2027, underpinned by accelerating adoption across existing and new treatment centers.
He also points to strategic initiatives that can further expand PEDMARK’s market, including an enlarged commercial team in the U.S., expected European royalties starting this year, and a planned Japanese registration with potential launch around 2027. In addition, ongoing and upcoming clinical and real‑world studies in broader cancer populations are viewed as catalysts that can strengthen PEDMARK’s role in standard-of-care, supporting his conviction that the shares remain undervalued at current levels.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 20.7% and a 52.09% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Aclaris Therapeutics, and Idorsia Ltd.
In another report released on March 25, Piper Sandler also reiterated a Buy rating on the stock with a $18.00 price target.